Key Takeaway: Zymeworks announced a corporate update highlighting a U.S. PDUFA target action date for zanidatamab, which could lead to a $250 million milestone upon approval. Additionally, the company anticipates closing its acquisition of Theravance Biopharma, Inc. in the second half of 2026, which may strengthen its market position.
Market Sentiment Analysis
POSITIVE FACTORS
Potential $250 million U.S. approval milestone for zanidatamab.
Up to $190 million in additional global regulatory milestones.
Acquisition of Theravance Biopharma expected to enhance portfolio.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+21%
120-day peak, hindsight
Typical move
5.1%
average across 6 past catalysts
Cash runway
~26 mo
Minimal dilution risk
Lead asset
Futibatinib
Phase 3 · Biliary Tract Neoplasms
Full Press Release Details
August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestones Acquisition of Theravance Biopharma, Inc. expected to close in 2H 2026, adding durable
Frequently Asked Questions
What is the PDUFA target action date for zanidatamab?
The PDUFA target action date for zanidatamab is August 25, 2026.
What financial milestones could zanidatamab unlock?
Zanidatamab has the potential to unlock a $250 million U.S. approval milestone.
When is the acquisition of Theravance Biopharma expected to close?
The acquisition of Theravance Biopharma is expected to close in the second half of 2026.
What additional milestones are associated with zanidatamab?
Zanidatamab could also lead to up to $190 million in potential additional global regulatory milestones.